Literature DB >> 12449185

RSV bronchiolitis and risk of wheeze and allergic sensitisation in the first year of life.

U Schauer1, S Hoffjan, J Bittscheidt, A Köchling, S Hemmis, S Bongartz, V Stephan.   

Abstract

Severe respiratory syncytial virus (RSV) infection has been hypothesised to be a risk factor for the development of allergy and asthma, but epidemiological studies in older children have been inconclusive. The current study hypothesises that the effect of RSV bronchiolitis might be most prominent during the first year after bronchiolitis. Forty-two infants had experienced RSV bronchiolitis severe enough to cause hospitalisation. For each child with RSV infection, two controls were acquired from a birth cohort and matched for date of birth and sex. All the children were followed prospectively and underwent a follow-up examination at a mean age of 1 yr, which included physical examination, and serum immunoglobulin (Ig) E tests for common food and inhaled allergens. Risk factors for the development of recurrent wheezing and IgE antibodies were analysed for the whole group of 126 children. A positive test for IgE antibodies was noted in 14 of 42 (33%) RSV children and in 2 of 84 (2.3%) children in the control group. RSV bronchiolitis was the most important risk factor for allergic sensitisation. Likewise, 13 children (15.5%) of the RSV group and three (3.6%) children of the control group suffered from recurrent wheezing, and RSV bronchiolitis posed a considerable risk for recurrent wheezing. Severe respiratory syncytial virus bronchiolitis during the first year of life is an important risk factor for the development of recurrent wheezing and sensitisation to common allergens during the subsequent year.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12449185     DOI: 10.1183/09031936.02.00019902

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  46 in total

1.  Methods for monitoring dynamics of pulmonary RSV replication by viral culture and by real-time reverse transcription-PCR in vivo: Detection of abortive viral replication.

Authors:  Marina S Boukhvalova; Kevin C Yim; Gregory A Prince; Jorge C G Blanco
Journal:  Curr Protoc Cell Biol       Date:  2010-03

2.  Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.

Authors:  Rebekka Kohlmann; Sarah Schwannecke; Bettina Tippler; Nicola Ternette; Vladimir V Temchura; Matthias Tenbusch; Klaus Uberla; Thomas Grunwald
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

3.  Determinants of asthma after severe respiratory syncytial virus bronchiolitis.

Authors:  Leonard B Bacharier; Rebecca Cohen; Toni Schweiger; Huiquing Yin-Declue; Chandrika Christie; Jie Zheng; Kenneth B Schechtman; Robert C Strunk; Mario Castro
Journal:  J Allergy Clin Immunol       Date:  2012-03-22       Impact factor: 10.793

Review 4.  Mechanisms how mucosal innate immunity affects progression of allergic airway disease.

Authors:  Allan R Brasier
Journal:  Expert Rev Respir Med       Date:  2019-02-13       Impact factor: 3.772

Review 5.  The role of the respiratory syncytial virus in airway syndromes in childhood.

Authors:  Mark L Everard
Journal:  Curr Allergy Asthma Rep       Date:  2006-03       Impact factor: 4.806

6.  Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus.

Authors:  Teresa R Johnson; Christina N Johnson; Kizzmekia S Corbett; Gretchen C Edwards; Barney S Graham
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

7.  Differential response of human naive and memory/effector T cells to dendritic cells infected by respiratory syncytial virus.

Authors:  T Rothoeft; K Fischer; S Zawatzki; V Schulz; U Schauer; C Körner Rettberg
Journal:  Clin Exp Immunol       Date:  2007-09-24       Impact factor: 4.330

Review 8.  Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma.

Authors:  Shyam S Mohapatra; Sandhya Boyapalle
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 9.  Understanding the mechanisms of viral induced asthma: new therapeutic directions.

Authors:  Nicole G Hansbro; Jay C Horvat; Peter A Wark; Philip M Hansbro
Journal:  Pharmacol Ther       Date:  2008-01-29       Impact factor: 12.310

10.  NGF is an essential survival factor for bronchial epithelial cells during respiratory syncytial virus infection.

Authors:  Sreekumar Othumpangat; Laura F Gibson; Lennie Samsell; Giovanni Piedimonte
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.